Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
aHUS observational registry of long-term safety and effectiveness of eculizumab
MOH_2017-02-13_000111Phase 4Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of eculizumab in atypical hemolytic uremic syndrome (aHUS) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoints: Long-term safety of eculizumab and Long-term effectiveness of eculizumab. Started Jan 2013; status: recruiting.
02
Drugs
eculizumab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on MOH_2017-02-13_000111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-02-13_000111.